Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19
Go back to Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 3.25 +0.01 (0.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.24 | 52 Week High | $54.24 | |||
| Open | $3.23 | 52 Week Low | $48.35 | |||
| Day High | $3.26 | P/E | N/A | |||
| Day Low | $3.18 | EPS | $0.00 | |||
| Volume | 12,176,851 | |||||
